reference/12665675

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12665675

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	2207
issn	1097-0142 0008-543X
issueIdentifier	9
pageRange	2201-2207
publicationName	Cancer
startingPage	2201
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b4a49f0ceadae2893d5423046803eebe http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_cfc2e0757d109dfcffe7a7fb765d5d56 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_1c26e7a83451e70c4c51cf69de45473c
bibliographicCitation	Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010 May 01;116(9):2201–7. PMID: 20166206; PMCID: PMC2861142.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48f1317294e39f37b65d46ca021324f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8eaaa7604c8883cda81dfeb8a1ed8dfd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9ab956db25f245168340000ecebd603 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_68a2caffbfcaa6534ea09ea429b3eda2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e8abcebcf8eeba5ea36bbb136feaec8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e348acc4664cedbb15de81ba694a15a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ddf84fb6b22c923096f8d6fa6c9a50b7
date	2010-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/cncr.25005 https://pubmed.ncbi.nlm.nih.gov/20166206 https://pubmed.ncbi.nlm.nih.gov/PMC2861142
isPartOf	https://portal.issn.org/resource/ISSN/0008-543X https://portal.issn.org/resource/ISSN/1097-0142 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M000602394 http://id.nlm.nih.gov/mesh/M0029863
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015451Q000188 http://id.nlm.nih.gov/mesh/D020123Q000031 http://id.nlm.nih.gov/mesh/D000970Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D015451Q000473 http://id.nlm.nih.gov/mesh/D000068338 http://id.nlm.nih.gov/mesh/D020123Q000627 http://id.nlm.nih.gov/mesh/D019008 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D018655 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008198Q000473 http://id.nlm.nih.gov/mesh/D012008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6590

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248184126 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214

Total number of triples: 60.